INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, cilt.71, sa.5, 2017 (SCI-Expanded)
Aims/objectives: In the BESIDE study, combination therapy (antimuscarinic [solifenacin] and beta(3)-adrenoceptor agonist [mirabegron]) improved efficacy over solifenacin monotherapy without exacerbating anticholinergic side effects in overactive bladder (OAB) patients; however, a potential synergistic effect on the cardiovascular (CV) system requires investigation.